Matching articles for "Ticarcillin/clavulanate"
Drugs for Bacterial Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2013; (Issue 131)
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Drugs for Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • July 23, 2012; (Issue 1395)
The most recent guidelines from the Infectious
Diseases Society of America (IDSA) and its European
counterpart on the choice of antimicrobials for treatment
of uncomplicated urinary tract infections (UTIs)...
The most recent guidelines from the Infectious
Diseases Society of America (IDSA) and its European
counterpart on the choice of antimicrobials for treatment
of uncomplicated urinary tract infections (UTIs) in
non-pregnant women focus on the unnecessary use of
fluoroquinolones to treat uropathogens that are
increasingly becoming resistant to them. Resistance
of Escherichia coli to ciprofloxacin in the US has
increased from 3% in 2000 to 17.1% in 2010.
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The Medical Letter on Drugs and Therapeutics • January 24, 2011; (Issue 1356)
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by...
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by methicillin-resistant
Staphylococcus aureus (MRSA), and for treatment of
community-acquired bacterial pneumonia in adults. It
is the first beta-lactam antibiotic approved for treatment
of MRSA.